3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
119
Squamous Cell Carcinoma of Head and Neck
60
Melanoma
57
Parkinson Disease 4, Autosomal Dominant Lewy Body
46
Lung Neoplasms
45
Triple Negative Breast Neoplasms
44
Neoplasm Metastasis
42
Breast Neoplasms
40
Neoplasms
36
Colorectal Neoplasms
31
Head and Neck Neoplasms
27
Endometrial Neoplasms
26
Carcinoma, Renal Cell
26
Ovarian Neoplasms
23
Carcinoma, Transitional Cell
22
Urinary Bladder Neoplasms
20
Stomach Neoplasms
15
Carcinoma
14
Pancreatic Neoplasms
13
Uterine Cervical Neoplasms
12
Recurrence
12
Esophageal Neoplasms
12
Sarcoma
11
Hodgkin Disease
11
Brain Neoplasms
11
Carcinoma, Squamous Cell
10
Cholangiocarcinoma
9
Carcinoma, Hepatocellular
9
Skin Neoplasms
8
Esophageal Squamous Cell Carcinoma
8
Interventions
pembrolizumab
1
fludarabine phosphate
1
fludarabine
1
abemaciclib
1
Nivolumab
1
Injections
1
Erlotinib Hydrochloride
1
Docetaxel
1
Cyclophosphamide
1
Cisplatin
1
Cetuximab
1
Biological Products
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Squamous Cell
×
pembrolizumab
×
90 days
×
Clear all
NCT06790966
2026-04-06
VERSATILE-003
PDS Biotechnology Corp.
Phase 3
Active not recruiting
252 enrolled